David Cunningham
Impact in
- Oncology top 0.01%
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Gastroenterology top 0.02%
- Gastrointestinal Tumor Research and Treatment
Papers in
- Oncology 702
- Colorectal Cancer Treatments and Studies 389
- Cancer Treatment and Pharmacology 127
- Pancreatic and Hepatic Oncology Research 111
-
- Gastric Cancer Management and Outcomes 320
- Lung Cancer Treatments and Mutations 101
- Co-authors
- Ian Chau (230 shared papers)Timothy Iveson (40 shared papers)Eric Van Cutsem (71 shared papers)William Allum (42 shared papers)Elizabeth Smyth (54 shared papers)A. Norman (65 shared papers)Naureen Starling (129 shared papers)M. Nicolson (23 shared papers)
- Journals
- Journal of Clinical Oncology (249 papers)Annals of Oncology (132 papers)British Journal of Cancer (76 papers)European Journal of Cancer (63 papers)Blood (36 papers)
- Partner nations
- United KingdomUnited StatesFrance
In The Last Decade
David Cunningham
1.2k papers receiving 75.9k citations
David Cunningham's Hit Papers
Peers
Comparison fields: 5 of 194
- Oncology 42.1k
- Gastroenterology 6.4k
- Pulmonary and Respiratory Medicine 30.7k
- Hepatology 6.3k
- Pathology and Forensic Medicine 13.7k
Countries citing papers authored by David Cunningham
This map shows the geographic impact of David Cunningham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Cunningham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Cunningham more than expected).
Fields of papers citing papers by David Cunningham
This network shows the impact of papers produced by David Cunningham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Cunningham. The network helps show where David Cunningham may publish in the future.
Co-authors
The 25 scholars most cited alongside David Cunningham, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 1.2k papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer Hit paper breakdown → | 2006 | 4494 |
| 2 | Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer Hit paper breakdown → | 2004 | 3874 |
| 3 | Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer Hit paper breakdown → | 2010 | 3000 |
| 4 | Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial Hit paper breakdown → | 2000 | 2530 |
| 5 | Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer Hit paper breakdown → | 2008 | 1727 |
| 6 | Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial Hit paper breakdown → | 2014 | 1715 |
| 7 | Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status Hit paper breakdown → | 2011 | 1441 |
| 8 | Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study Hit paper breakdown → | 2010 | 1351 |
| 9 | Colorectal cancer Hit paper breakdown → | 2010 | 1138 |
| 10 | Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2010 | 1084 |
| 11 | Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2016 | 1083 |
| 12 | The role of probiotics in aquaculture Hit paper breakdown → | 2006 | 1032 |
| 13 | Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer Hit paper breakdown → | 1998 | 973 |
| 14 | Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial Hit paper breakdown → | 2009 | 893 |
| 15 | Oesophageal cancer Hit paper breakdown → | 2017 | 831 |
| 16 | SRT1720, SRT2183, SRT1460, and Resveratrol Are Not Direct Activators of SIRT1 Hit paper breakdown → | 2010 | 723 |
| 17 | Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. Hit paper breakdown → | 1997 | 691 |
| 18 | Oesophageal cancer Hit paper breakdown → | 2017 | 691 |
| 19 | Kirsten ras Mutations in Patients With Colorectal Cancer: the Multicenter "RASCAL" Study Hit paper breakdown → | 1998 | 613 |
| 20 | Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Hit paper breakdown → | 1998 | 603 |
About David Cunningham
David Cunningham is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Surgery, Pathology and Forensic Medicine and Cancer Research, having authored 1.2k papers that have together received 77.9k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (389 papers), Gastric Cancer Management and Outcomes (320 papers), Lymphoma Diagnosis and Treatment (161 papers), Esophageal Cancer Research and Treatment (130 papers), Cancer Treatment and Pharmacology (127 papers), Colorectal and Anal Carcinomas (127 papers), Pancreatic and Hepatic Oncology Research (111 papers) and Lung Cancer Treatments and Mutations (101 papers). The work is most often cited by research in Oncology (42.1k citations), Gastroenterology (6.4k citations), Pulmonary and Respiratory Medicine (30.7k citations), Hepatology (6.3k citations) and Pathology and Forensic Medicine (13.7k citations). David Cunningham has collaborated with scholars based in United Kingdom, United States and France. Frequent co-authors include Ian Chau, Timothy Iveson, Eric Van Cutsem, William Allum, Elizabeth Smyth, A. Norman, Naureen Starling, M. Nicolson, Alicia Okines and Andrés Cervantes. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, British Journal of Cancer, European Journal of Cancer and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.